Aberrant response in vitro of hormone‐responsive prostate cancer cells to antiandrogens

George Wilding, Michael Chen, Edward P. Gelmann

Research output: Contribution to journalArticlepeer-review

190 Scopus citations


Antiandrogens are in use alone and in combination with other agents as hormonal therapy for prostate cancer. We conducted studies on the androgen‐responsive human prostate cancer cell line LNCaP to determine the direct effects of three antiandrogens (hydroxyflutamide, RU23908, and cyproterone acetate) on hormone‐responsive human prostate cancer cells in culture. Dihydrotestosterone (DHT) stimulated the growth of LNCaP cells in a dose‐dependent fashion. These cells contained approximately 31,000 high‐affinity (Kd = 9 × 10−10 M) androgen binding sites per cell. In the absence of any androgenic stimulation, all three antiandrogens tested showed agonistic properties by increasing the cell number and uptake of [3H]‐thymidine. Competitive uptake studies using [3H]‐R1881, a nonmetabolized androgen, showed that the three antiandrogens inhibited specific R1881 uptake with IC50s of 0.9 × 10−7 M for hydroxyflutamide, 2 × 10−7 M for RU23908, and 1 × 10−7 M for cyproterone acetate. It is not known whether these unexpected agonistic effects are due to an altered receptor, previously unmasked agonistic properties of the antiandrogens, or emergence of a hypersensitive clone of cells.

Original languageEnglish (US)
Pages (from-to)103-115
Number of pages13
JournalThe Prostate
Issue number2
StatePublished - 1989
Externally publishedYes


  • LNCaP cells
  • RU23908
  • cyproterone acetate
  • dihydrotestosterone
  • hydroxyflutamide

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Aberrant response in vitro of hormone‐responsive prostate cancer cells to antiandrogens'. Together they form a unique fingerprint.

Cite this